Form 4 for INCY Incyte
Accepted 2025-01-08 00:00:00 ET · period of report 2025-01-06 · accession 0000879169-25-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-08 | 2025-01-06 | INCY | Issa Mohamed Khairie | EVP, Head of US Oncology | A - Grant | $0.00 | +48.7K | 48.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | A | A | 48,671 | $0.00 | 48,671 | D | — | — | (F1) Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. (F2) Includes the January 6, 2025 aggregate grant of 48,671 shares of common stock. |